AstraZeneca to update on progress with immuno-oncology pipeline and combination treatments at 2015 ASCO Annual Meeting

Wednesday, 13 May 2015

• 61 data abstracts - with 6 oral presentations - to be featured from across AstraZeneca’s broad pipeline, including in lung, ovarian and breast cancers.
• Increased confidence in the potential of anti-PD-L1 MEDI4736 as a cornerstone for combination treatments with other immuno-oncology and small molecule investigational medicines.
• Updated data will be presented on the safety and clinical activity of MEDI4736 + tremelimumab in patients with NSCLC.
• Data will also be presented on the safety of MEDI4736 in combination with EGFR inhibitors gefitinib and AZD9291, as well as the triple combination with trametinib (MEK inhibitor) + dabrafenib (BRAF inhibitor)¹.
• In small molecule combinations, data will be presented on AZD9291 with savolitinib (cMET inhibitor) or selumetinib (MEK inhibitor), being investigated as potential treatments for overcoming newly-identified forms of resistance in EGFR mutated lung cancer.

AstraZeneca and MedImmune, the Company’s global biologics research and development arm, will demonstrate rapid progress with their combination-focused oncology pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting, 29 May-2 June 2015. 61 scientific abstracts² will be presented at the meeting, reinforcing the significant progress in immuno-oncology through combination therapies and innovative companion diagnostics.

Briggs Morrison, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “We are pleased to update on the breadth and depth of our oncology pipeline at ASCO. Our small molecule and biologic treatments target multiple areas of tumour biology across a diverse range of cancers, alone or in combination. It is especially encouraging to see the potential impact of our work in non-small cell lung cancer at different stages of the disease pathway and for different types of patients.”

“In immuno-oncology, we are starting to see the transformational potential of combination therapies, which are at the heart of our vision of redefining cancer treatment. The maturing data reinforce our confidence in this strategy, and, in particular, in MEDI4736, which is showing durable activity across multiple tumour types and in different combinations. This progress offers the possibility of helping patients who don’t respond to standard of care or current monotherapies.”

Bahija Jallal, Executive Vice President, MedImmune, said: “Our understanding of the potential of immuno-oncology is fast evolving as we begin to unlock its benefits for a greater number of patients – however we have only scratched the surface so far. Our comprehensive, combination-focused development programme aims to rapidly deepen our scientific understanding, exploring all the critical areas of the immune system that cancer can hijack to escape destruction. Through the use of companion diagnostics, we can also fully understand the clinical value of our investigational immunotherapies, both as monotherapy and in combination, for different types of patients and across many different types of cancer.”

Highlights at the ASCO Annual Meeting will include data from across the Company’s broad pipeline of next-generation investigational medicines, which target cancer through key areas of tumour biology including immunotherapy, the genetic drivers of cancer and acquired resistance and DNA damage repair.

Immuno-oncology

Immunotherapies use the body's own immune system to help fight cancer. There are three major components to an effective cancer immune response: priming and activation of T-cells (white blood cells that play a central role in immune response) through cancer antigen presentation; optimising T-cell mediated cancer cell killing by overcoming inhibitory mechanisms employed by the cancer; and overcoming immune suppressive mechanisms in the tumor microenvironment to further enhance an effective anti-tumour immune response.

At the ASCO Annual Meeting AstraZeneca will provide an update on its comprehensive immuno-oncology development programme, which includes 31 ongoing clinical trials targeted across this cycle of anti-tumour immunity. Data to be presented at ASCO are supported by a number of recent milestones including:

• Start of the combination arm of the Phase III ARCTIC study of MEDI4736 with tremelimumab in non-small cell lung cancer (NSCLC) patients who have received at least two prior systemic treatment regimens.
• Start of the Phase II CONDOR study of MEDI4736 and tremelimumab as monotherapies and in combination in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN).
• Fast-Track designation granted by the FDA for the investigation of MEDI4736 as a monotherapy treatment for patients with advanced NSCLC, who have received at least two prior systemic-treatment regimens, who do not have EGFR mutations or anaplastic lymphoma kinase (ALK) alterations, and have tumours that are determined to be PD-L1 positive.
• In addition to testing the potential of immunotherapies in solid tumours, AstraZeneca recently entered into a strategic collaboration with Celgene, a global leader in haematological cancers, on a broad development programme for MEDI4736, both as monotherapy and in combination with other molecules, across a range of blood cancers including multiple myeloma, non-Hodgkin’s lymphoma and myelodysplastic syndrome.

Presentations to include:

• Safety and efficacy of MEDI4736 in combination with tremelimumab in patients with NSCLC [Abstract #3014]. Updated data on additional patients and activity in both PD-L1 positive and negative patients to be presented.
• Safety and efficacy of the triple combination of MEDI4736 with BRAF (dabrafenib) and/or MEK (trametinib) inhibitors in patients with advanced melanoma [Oral Abstract #3003].
• An open-label study of MEDI4736 in combination with MEDI0680 (anti-PD-1) in patients with advanced malignancies [Trials in Progress Poster #TPS3087].
• Updates reinforcing the clinical activity of MEDI4736 as monotherapy in patients with NSCLC [Abstract #8032], in patients with recurrent or metastatic SCCHN [Abstract #3011], and on the development of a PD-L1 companion diagnostic assay [Abstract #8033].

Genetic drivers of cancer and resistance

AstraZeneca has a strong legacy in research into the genetic drivers of cancer and resistance. Iressa (gefitinib) was the first epidermal growth factor receptor (EGFR) inhibitor, providing the first truly targeted treatment for advanced lung cancer. Data to be presented at ASCO will focus on AZD9291, an investigational, highly selective, irreversible inhibitor of both the activating sensitising EGFR mutation (EGFRm) and the activating resistance mutation, T790M.

Patients with EGFRm NSCLC are particularly sensitive to treatment with currently available EGFR tyrosine kinase inhibitors (TKIs), which block the cell signalling pathways that drive the growth of tumour cells. However, tumour cells almost always develop resistance to treatment, leading to disease progression. In approximately two thirds of patients, this resistance is caused by the secondary mutation, T790M. No currently targeted therapies are approved for the treatment of tumours with this resistance mutation.

AZD9291 presentations at ASCO to include:

• Early efficacy and safety data from the multi-arm Phase Ib TATTON study, testing AZD9291 in combination with one of three treatments in patients with advanced, EGFR-mutant NSCLC who have progressed on prior EGFR TKI therapy [Abstract #2509]. The treatments are MEDI4736; savolitinib (AZD6094), an investigational, highly potent and selective c-MET inhibitor; or selumetinib, a potent, selective inhibitor of MEK1/2 kinases.
• Detail on the Phase III FLAURA clinical trial testing AZD9291 versus standard doses of gefitinib or erlotinib in treatment-naïve patients with EGFR-mutant advanced NSCLC [Trials in Progress Poster #TPS8102].
• Data from the Phase I AURA study testing AZD9291 as first-line therapy for patients with NSCLC, compared against currently approved EGFR medicines [Abstract #8000].

Data presented at ASCO build on the updated progression-free survival (PFS) data for AZD9291 as second line therapy for patients with EGFR-mutated NSCLC, who also have the T790M resistance mutation, which was presented at the recent European Lung Cancer Conference. The data demonstrated a median PFS of 13.5 months (95% confidence interval (CI) 8.3 months to not calculable (NC)). These PFS findings relate to independently reviewed data from 63 patients with T790M tumours treated with AZD9291 at a dose of 80mg per day, and are based on only 38% of patients having tumour progression. In patients treated with AZD9291 80mg, the most common all-cause adverse events (AEs) of any grade were rash, 38% (0% Grade ≥3) and diarrhea, 36% (1% Grade ≥3). Investigator-determined treatment-related Grade ≥3 AEs occurred in 14% of patients.

DNA Damage Repair

AstraZeneca has the largest portfolio of potential medicines targeted at DNA damage repair, including the recently launched Lynparza (olaparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, for BRCA-mutated ovarian cancer.

During ASCO, new data will be presented on Lynparza and on AZD1775, a small molecule designed to inhibit the tyrosine kinase called Wee1, which helps to regulate the cell-division cycle, and is undergoing testing for the treatment of ovarian cancer. AZD1775 is designed to cause certain tumour cells to divide without undergoing the normal DNA repair processes, ultimately leading to cell death. Preclinical evidence suggests that the combination of AZD1775 and DNA damage-inducing chemotherapy agents can enhance anti-tumour properties, in comparison to chemotherapy alone.

• Data on the genomic characterisation of long-term responders to Lynparza will provide further insight into the physiology of ovarian cancer patients seeing benefit from the medicine [Abstract #5566].
• Data from an international biomarker-directed randomised Phase II trial of AZD1775 used in combination with paclitaxel and carboplatin for the treatment of women with platinum-sensitive, TP53 mutated ovarian cancer [Oral Abstract #5506].
• Data from a Phase II study of AZD1775 plus carboplatin in patients with TP53 mutated ovarian cancer refractory or resistant (three or fewer months) to standard first line therapy [Oral Abstract #2507].

Key AstraZeneca abstracts to be featured at ASCO

Molecule Indication Abstract #, Title and Author* Time (CDT) / Location Immunotherapy MEDI4736 Squamous cell carcinoma of the head and neck Abstract #3011
Safety and efficacy of MEDI4736, an anti-PD-L1 antibody, in patients from a squamous cell carcinoma of the head and neck (SCCHN) expansion cohort.
Segal N.H., et al. Saturday 30 May
8:00 AM – 11:30 AM
Location: S Hall A
Poster Session: Developmental Therapeutics – Immunotherapy
Poster Discussion:
3:00 PM – 4:15 PM
Location: S406
Poster Board#: 337 MEDI4736 + tremelimumab Advanced NSCLC Abstract #3014
Phase Ib study of MEDI4736, a programmed cell death ligand-1 (PD-L1) antibody, in combination with tremelimumab, a cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) antibody, in patients (pts) with advanced NSCLC.
Antonia S.J., et al. Saturday 30 May
8:00 AM– 11:30 AM
Location: S Hall A
Poster Session: Developmental Therapeutics – Immunotherapy
Poster Discussion:
3:00 PM– 4:15 PM
Location: S406
Poster Board#: 340 MEDI4736 Squamous cell carcinoma of the head and neck Abstract #TPS3090
Phase I study to evaluate the safety and efficacy of MEDI4736 in combination with tremelimumab in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN).
Siu L.L., et al. Saturday 30 May
8:00 AM–11:30 AM
Location: S Hall A
Poster Session: Developmental Therapeutics - Immunotherapy
Poster Board#: 414b MEDI4736 Advanced solid tumours Abstract #3039
Phase I study to evaluate the safety and tolerability of MEDI4736, an anti-programmed cell death ligand-1 (PD-L1) antibody, in Japanese patients with advanced solid tumors.
Iguchi H., et al. Saturday 30 May
8:00 AM–11:30 AM
Location: S Hall A
Poster Session: Developmental Therapeutics – Immunotherapy
Poster Board#: 365 MEDI4736 NSCLC Abstract #3047
Safety and tolerability results from a phase I study of MEDI4736, a human IgG1 anti-programmed cell death-ligand-1 (PD-L1) antibody, combined with gefitinib in patients (pts) with non-small-cell lung cancer (NSCLC).
Creelan B.C., et al. Saturday 30 May
8:00 AM–11:30 AM
Location: S Hall A
Poster Session: Developmental Therapeutics – Immunotherapy
Poster Board#: 373 MEDI4736 + MEDI0680 Advanced malignancies Abstract #TPS3087
Phase I, open-label study of MEDI0680, an anti-programmed cell death-1 antibody, in combination with MEDI4736, an anti-programmed cell death ligand-1 antibody, in patients with advanced malignancies.
Hamid O., et al. Saturday 30 May
8:00 AM–11:30 AM
Location: S Hall A
Poster Session: Developmental Therapeutics – Immunotherapy
Poster Board#: 413a MEDI4736 Myelodysplastic Syndrome (MDS) Abstract #TPS7103
Phase 1 study to evaluate the safety and tolerability of MEDI4736, an anti-programmed cell death ligand-1 (PD-L1) antibody, in myelodysplastic syndrome (MDS) after treatment with hypomethylating agents.
Garcia-Manero G., et al. Sunday 31 May
8:00 AM–11:30 AM
Location: S Hall A
Poster Session: Leukemia, Myelodysplasia, and Transplantation
Poster Board#: 87b MEDI4736 Advanced NSCLC Abstract #TPS8104
A phase III study of MEDI4736 (M), an anti-PD-L1 antibody, in monotherapy or in combination with Tremelimumab (T), versus standard of care (SOC) in patients (pts) with advanced non-small cell lung cancer (NSCLC) who have received at least two prior systemic treatment regimens (ARCTIC).
Planchard D., et al. Monday 1 June
8:00 AM–11:30 AM
Location: S Hall A
Poster Session: Lung Cancer—Non-Small Cell Metastatic
Poster Board#: 428a MEDI4736 NSCLC Abstract #8032
Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with NSCLC.
Rizvi N.A., et al. Monday 1 June
8:00 AM–11:30 AM
Location: S Hall A
Poster Session: Lung Cancer—Non-Small Cell Metastatic
Poster Board#: 354 MEDI4736 NSCLC and Squamous cell carcinoma of the head and neck Abstract #8033
Development of a PD-L1 companion diagnostic assay for treatment with MEDI4736 in NSCLC and SCCHN patients.
Rebelatto M., et al. Monday 1 June
8:00 AM–11:30 AM
Location: S Hall A
Poster Session: Lung Cancer—Non-Small Cell Metastatic
Poster Board#: 355 MEDI4736 Melanoma Abstract #3003
Phase I study combining anti-PD-L1 (MEDI4736) with BRAF (dabrafenib) and/or MEK (trametinib) inhibitors in advanced melanoma.
Ribas A., et al. Monday 1 June
1:15 PM – 4:15 PM
Location: S406
Oral Abstract Session: Developmental Therapeutics – Immunotherapy
Oral Presentation:
2:15 PM - 2:27 PM MEDI4736 Glioblastoma (GMB) Abstract #TPS2077
Phase II study to evaluate the clinical efficacy and safety of MEDI4736 in patients with glioblastoma (GBM).
Reardon D.A., et al. Monday 1 June
1:15PM – 4:45PM Location: S Hall A
Poster Session: Central Nervous System Tumors
Poster Board#: 66b Genetic drivers of cancer and resistance AZD9291 Advanced NSCLC Abstract #2509
Preliminary results of TATTON, a multi-arm phase Ib trial of AZD9291 combined with MEDI4736, AZD6094 or selumetinib in EGFR-mutant lung cancer.
Oxnard G.R., et al. Saturday 30 May
8:00 AM–11:30 AM
Location: S Hall A
Poster Session: Developmental Therapeutics – Clinical Pharmacology and Experimental Therapeutics
Poster Discussion:
1:15 PM–2:30 PM
Location: S406
Poster Board#: 225 AZD5363 Advanced solid malignancies Abstract #2577
Results of OAK: A phase 1, open-label, multicenter study to compare two dosage forms of AZD5363 and to explore the effect of food on the pharmacokinetic (PK) exposure, safety, and tolerability of AZD5363 in patients with advanced solid malignancies.
Dean E.J., et al. Saturday 30 May
8:00 AM–11:30 AM
Location: S Hall A
Poster Session: Developmental Therapeutics – Clinical Pharmacology and Experimental Therapeutics
Poster Board#: 293 Selumetinib Solid Tumours Abstract #2583
A phase I dose escalation study of the tolerability of the oral VEGFR and EGFR inhibitor vandetanib (V) in combination with the oral MEK inhibitor selumetinib (S) in solid tumors.
Saka W.O,, et al. Saturday 30 May
8:00 AM–11:30 AM
Location: S Hall A
Poster Session: Developmental Therapeutics – Clinical Pharmacology and Experimental Therapeutics
Poster Board#: 299 AZD9291 Advanced NSCLC Abstract #8000
AZD9291, a mutant-selective EGFR inhibitor, as first-line treatment for EGFR mutation-positive advanced non-small cell lung cancer: Results from a phase 1 expansion cohort.
Ramalingam S.S., et al. Sunday 31 May
8:00 AM–11:00 AM
Location: N Hall B1
Oral Abstract Session: Lung Cancer – Non-Small Cell Metastatic
Oral Presentation:
8:00 AM – 8:12 AM AZD4547 FGFR amplified
tumours Abstract #4014
A randomized, open-label phase II study of AZD4547 (AZD) versus Paclitaxel (P) in previously treated patients with advanced gastric cancer (AGC) with Fibroblast Growth Factor Receptor 2 (FGFR2) polysomy or gene amplification (amp): SHINE study.
Bang Y-J., et al. Monday 1 June
8:00 AM–11:30 AM
Location: S Hall A
Poster Session: Gastrointestinal (Noncolorectal) Cancer
Poster Discussion: 3:00PM-4:15PM
Location: E Hall D1
Poster Board#: 123 AZD3759 NSCLC and brain metastasis Abstract #8016
AZD3759, an EGFR inhibitor with blood brain barrier (BBB) penetration for the treatment of non-small cell lung cancer (NSCLC) with brain metastasis (BM): Preclinical evidence and clinical cases.
Kim D-W., et al. Monday 1 June
8:00 AM–11:30 AM
Location: S Hall A
Poster Session: Lung Cancer – Non-Small Cell Metastatic
Poster Discussion: 3.00PM - 4.15PM
Location: E Hall D2
Poster Board#: 338 AZD8931 Oesophago-gastric adenocarcinoma Abstract #4037
A phase I dose-escalating and safety study of AZD8931 in combination with oxaliplatin and capecitabine chemotherapy in patients with oesophago-gastric adenocarcinoma.
Thomas A.L., et al. Monday 1 June
8:00 AM–11:30 AM
Location: S Hall A
Poster Session: Gastrointestinal (Noncolorectal) Cancer
Poster Board#: 146 AZD9291 Advanced NSCLC Abstract #TPS8102
A randomized, Phase III study (FLAURA) of AZD9291, a novel EGFR-TKI, versus gefitinib or erlotinib in treatment-naïve patients with advanced non-small cell lung cancer and an EGFR-TKI-sensitizing mutation
Ramalingam S., et al. Monday 1 June
8:00 AM–11:30 AM
Location: S Hall A
Poster Session: Lung Cancer – Non-Small Cell Metastatic
Poster Board#: 427a Selumetinib Advanced NSCLC Abstract #8046
A phase Ib study of selumetinib in patients (pts) with previously untreated metastatic Non-Small Cell Lung Cancer (NSCLC) receiving standard chemotherapy: NCIC Clinical Trials Group IND.215. NCT01783197.
Nicholas G.A.N., et al. Monday 1 June
8:00 AM–11:30 AM
Location: S Hall A
Poster Session: Lung Cancer – Non-Small Cell Metastatic
Poster Board#: 369 AZD5363 Breast and gynecological cancers Abstract #2500
A pharmacokinetically (PK) and pharmacodynamically (PD) driven phase I trial of the pan-AKT inhibitor AZD5363 with expansion cohorts in PIK3CA mutant breast and gynecological cancers.
Banerji U., et al. Tuesday 2 June
8:00 AM–11:00 AM
Location: S100a
Oral Abstract Session: Developmental Therapeutics - Clinical Pharmacology and Experimental Therapeutics Oral Presentation:
8:00 AM – 8:12 AM AZD4547 FGFR amplified
tumours Abstract #2508
Phase II multicenter proof of concept study of AZD4547 in FGFR amplified tumours.
Smyth EC., et al. Tuesday 2 June
8:00 AM–11:00 AM
Location: S100a
Oral Abstract Session: Developmental Therapeutics – Clinical Pharmacology and Experimental Therapeutics
Oral Presentation:
10:12 AM – 10:24 AM DNA damage repair    Lynparza (olaparib) Breast Cancer Abstract #1038
A phase I/II trial of olaparib in combination with eribulin in patients with advanced or metastatic triple negative breast cancer (TNBC) previously treated with anthracyclines and taxanes: First results from phase I.
Yasojima H., et al. Saturday 30 May
8:00 AM – 11:30 AM
Location: S Hall A
Poster Session: Breast Cancer - Triple-Negative/Cytotoxics/Local Therapy
Poster Board#: 152 Lynparza (olaparib) Breast Cancer Abstract #TPS1109
OlympiA: A randomized phase III trial of olaparib as adjuvant therapy in patients with high-risk HER2-negative breast cancer (BC) and a germline BRCA1/2 mutation (gBRCAm).
Tutt A.N.J., et al. Saturday 30 May
8:00 AM – 11:30 AM
Location: S Hall A
Poster Session: Breast Cancer - Triple-Negative/Cytotoxics/Local Therapy
Poster Board#: 218b Lynparza (olaparib) Advanced solid tumours Abstract #2565
Effect of itraconazole and rifampin on the pharmacokinetics of olaparib tablet formulation in patients with advanced solid tumours: Phase I open-label studies.
Plummer E.R., et al. Saturday 30 May
8:00 AM – 11:30 AM
Location: S Hall A
Poster Session: Developmental Therapeutics - Clinical Pharmacology and Experimental Therapeutics
Poster Board#: 281 Lynparza (olaparib) Ovarian Cancer Abstract #5514
Phase I/Ib study of the PARP inhibitor (PARPi) olaparib (O) with carboplatin (C) in heavily pretreated high-grade serous ovarian cancer (HGSOC) at low genetic risk (NCT01445418).
Chiou V.L., et al. Saturday 30 May
1:15 PM – 4:45 PM
Location: S Hall A
Poster Session: Gynecologic Cancer
Poster Discussion:
4:45 PM – 6:00 PM, Location: E354b
Poster Board#: 72 AZD1775 Ovarian Cancer Abstract #TPS5608
Multicenter randomized Phase II study of AZD1775 plus chemotherapy versus chemotherapy alone in patients with platinum-resistant TP53-mutated epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Moore K.N., et al. Saturday 30 May
1:15 PM – 4:45 PM
Location: S Hall A
Poster Session: Gynecologic Cancer
Poster Board#: 164b Lynparza (olaparib) Ovarian Cancer Abstract #5566
Genomic characterization of long-term responders to olaparib.
Lheureux S., et al. Saturday 30 May
1:15 PM–4:45 PM
Location: S Hall A
Poster Session: Gynecologic Cancer
Poster Board#: 124 AZD1775 Ovarian Cancer Abstract #5506
An international, biomarker-directed, randomized Phase II trial of AZD1775 plus paclitaxel and carboplatin for the treatment of women with platinum-sensitive, TP53-mutant ovarian cancer.
Oza A.M., et al. Monday 1 June
8:00 AM–11:00 AM
Location: E354b
Oral Abstract Session: Gynecologic cancer
Oral Presentation:
10:00 AM – 10:12 AM AZD1775 Ovarian Cancer Abstract #2507
Phase II study with Wee1 inhibitor AZD1775 plus carboplatin in patients with p53 mutated ovarian cancer refractory or resistant (<3 months) to standard first line therapy.
Leijen S., et al. Tuesday 2 June
8:00 AM–11:00 AM
Location: S100a
Oral Abstract Session: Developmental Therapeutics – Clinical Pharmacology and Experimental Therapeutics
Oral Presentation:
10:00 AM – 10:12 AM

NOTES FOR EDITORS

About AstraZeneca in Oncology

Oncology is a therapeutic area in which AstraZeneca has deep-rooted heritage. It will be potentially transformational for the Company’s future, becoming the sixth growth platform. Our vision is to help patients by redefining the cancer treatment paradigm and one-day eliminate cancer as cause of death. By 2020, we are aiming to bring six new cancer medicines to patients.

Our broad pipeline of next-generation investigational medicines is focused on four main disease areas - ovarian, lung, breast, and haematological cancers. These are being targeted through four key platforms – immuno-oncology, the genetic drivers of cancer and resistance, DNA damage repair and antibody drug conjugates.

About MedImmune

MedImmune is the worldwide biologics research and development arm of AstraZeneca. MedImmune is pioneering innovative research and exploring novel pathways across key therapeutic areas, including respiratory, inflammation and autoimmunity; cardiovascular and metabolic disease; oncology; neuroscience; and infection and vaccines. The MedImmune headquarters is located in Gaithersburg, Md., one of AstraZeneca’s three global R&D centres. For more information, please visit www.medimmune.com.

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com.

CONTACTS

¹ Novartis medicines for treatment of patients with metastatic melanoma.

² Data included in abstracts are preliminary only and do not represent full data sets.